23 October 2015 - Novartis announced today that the Committee for Medicinal Products for Human Use has recommended the approval of Cosentyx (secukinumab) in Europe to treat ankylosing spondylitis and psoriatic arthritis patients.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-il-17a-inhibitor-cosentyxtm-treat